Financials Repligen Corporation

Stocks

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 00:00:00 12/09/2026 +04			5-day change	1st Jan Change
165.18 ^USD	+0.30%		-1.44%	+0.81%

09-09	Repligen Corporation Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 01:30 PM
09-09	UBS Adjusts Price Target on Repligen to $225 From $195, Keeps Buy Rating	MT

Projected Income Statement: Repligen Corporation

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	670.5	801.5	638.8	634.4	738.3	826.9	974.4	1,145
Change	-	19.54%	-20.31%	-0.68%	16.36%	12.01%	17.83%	17.5%
EBITDA ¹	230.5	246.9	128	117.3	140.3	170.9	222.1	287.7
Change	-	7.1%	-48.18%	-8.36%	19.69%	21.74%	29.97%	29.57%
EBIT ¹	215.2	232.2	94.29	82.08	101.8	130.8	177	241.1
Change	-	7.91%	-59.4%	-12.95%	24.05%	28.46%	35.36%	36.2%
Interest Paid ¹	-12.71	-1.162	-1.951	-20.73	-21.51	-22.43	-21.25	-19.37
Earnings before Tax (EBT) ¹	153.5	219.1	64.13	-27.04	62.38	55.21	124.3	179.8
Change	-	42.72%	-70.73%	-142.16%	330.75%	-11.5%	125.21%	44.61%
Net income ¹	128.3	186	41.58	-25.51	48.89	41.92	98.84	141.2
Change	-	44.95%	-77.64%	-161.37%	291.64%	-14.26%	135.77%	42.87%
Announcement Date	17/02/22	22/02/23	21/02/24	20/02/25	24/02/26	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4
Net sales ¹	178.2	186.5	206.4	207.6	200.7	186.8	182.7	159.2	141.2	155.7	151.3	154.1	154.9	167.5	169.2	182.4	188.8	197.9	194.3	204.1	206.8	221.9	223.8	236.2	241.7	257
Change	-	4.66%	10.66%	0.6%	-3.32%	-6.96%	-2.2%	-12.86%	-11.29%	10.31%	-2.82%	1.8%	0.52%	8.18%	0.97%	7.8%	3.53%	4.82%	-1.85%	5.08%	1.32%	7.28%	0.88%	5.53%	2.32%	6.33%
EBITDA ¹	60.52	61.6	72.21	67.69	57.95	49.06	48.86	38.45	14.46	26.19	20.22	23.41	32	35.05	32.7	32.18	35.93	39.54	40.01	43.77	38.9	48.55	49	52.41	52.95	61.63
Change	-	1.79%	17.23%	-6.26%	-14.39%	-15.34%	-0.42%	-21.31%	-62.39%	81.15%	-22.78%	15.73%	36.74%	9.52%	-6.71%	-1.61%	11.66%	10.06%	1.19%	9.39%	-11.11%	24.78%	0.94%	6.95%	1.03%	16.41%
EBIT ¹	56.96	55.91	67.37	65.56	58.15	41.13	40.85	29.45	5.167	18.82	11.8	15.63	23.1	25	23.4	21.91	26.77	29.74	29.9	34	28.75	38.01	39.42	42.52	42.96	51.36
Change	-	-1.86%	20.5%	-2.69%	-11.29%	-29.28%	-0.67%	-27.92%	-82.45%	264.25%	-37.3%	32.42%	47.83%	8.22%	-6.38%	-6.38%	22.18%	11.08%	0.56%	13.71%	-15.46%	32.22%	3.73%	7.85%	1.04%	19.56%
Charge d'intérêts ¹	-3.22	-3.244	-0.744	-0.271	-0.329	-0.27	-0.727	-0.274	-0.269	-1.138	-4.891	-4.981	-5.122	-5.462	-5.25	-5.354	-5.414	-5.495	-5.578	-5.663	-5.611	-5.632	-5.283	-5.293	-5.303	-5.313
Earnings before Tax (EBT) ¹	41.23	34.85	58.93	59.76	47.47	52.99	36.09	25.16	11.64	-8.757	2.114	5.182	-1.148	-38.61	7.943	18.22	17.11	19.11	1.772	14.15	17.43	24.95	27.53	30.31	32.13	41.01
Change	-	-15.48%	69.11%	1.4%	-20.57%	11.63%	-31.88%	-30.29%	-53.75%	-175.25%	124.14%	145.13%	-122.15%	-3,263.07%	120.57%	129.32%	-6.06%	11.69%	-90.73%	698.7%	23.14%	43.18%	10.31%	10.1%	6.02%	27.64%
Net income ¹	33.5	29.11	46.96	49.86	40.4	48.73	28.83	20.06	18.17	-25.49	2.094	3.321	-0.653	-33.87	5.83	14.87	14.91	13.29	8.333	5.008	12.4	18.79	21.38	23.5	23.82	31.96
Change	-	-13.1%	61.33%	6.17%	-18.96%	20.6%	-40.84%	-30.4%	-9.43%	-240.26%	108.22%	58.6%	-119.66%	-5,086.68%	117.21%	154.99%	0.3%	-10.89%	-37.28%	-39.9%	147.68%	51.49%	13.79%	9.89%	1.37%	34.15%
Announcement Date	28/10/21	17/02/22	27/04/22	02/08/22	01/11/22	22/02/23	02/05/23	02/08/23	31/10/23	21/02/24	01/05/24	30/07/24	12/11/24	20/02/25	29/04/25	29/07/25	28/10/25	24/02/26	05/05/26	28/07/26	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Repligen Corporation

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt ¹	-238	-339	-682	-232	-23.8	-265	-438	-662
Change	-	-42.44%	-101.18%	65.98%	89.74%	-1,013.07%	-65.28%	-51.14%
Announcement Date	17/02/22	22/02/23	21/02/24	20/02/25	24/02/26	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Repligen Corporation

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
CAPEX ¹	67.09	84.83	36.22	25.68	23.52	26.93	32.74	37.79
Change	-	26.45%	-57.3%	-29.11%	-8.4%	14.5%	21.6%	15.42%
Free Cash Flow (FCF) ¹	51.93	87.25	77.7	149.7	93.9	120.6	149.5	199.2
Change	-	68.02%	-10.95%	92.7%	-37.28%	28.42%	23.99%	33.27%
Announcement Date	17/02/22	22/02/23	21/02/24	20/02/25	24/02/26	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Repligen Corporation

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	34.38%	30.8%	20.03%	18.48%	19.01%	20.66%	22.79%	25.13%
EBIT Margin (%)	32.09%	28.97%	14.76%	12.94%	13.79%	15.82%	18.17%	21.06%
EBT Margin (%)	22.9%	27.34%	10.04%	-4.26%	8.45%	6.68%	12.76%	15.7%
Net margin (%)	19.13%	23.2%	6.51%	-4.02%	6.62%	5.07%	10.14%	12.33%
FCF margin (%)	7.74%	10.89%	12.16%	23.6%	12.72%	14.58%	15.34%	17.4%
FCF / Net Income (%)	40.48%	46.92%	186.87%	-586.8%	192.04%	287.64%	151.26%	141.1%
Profitability
ROA	8.23%	7.72%	3.68%	3.14%	3.35%	2.56%	5.78%	4.75%
ROE	10.69%	10.3%	5.07%	4.51%	4.75%	4.63%	8.03%	7.9%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	10.01%	10.58%	5.67%	4.05%	3.19%	3.26%	3.36%	3.3%
CAPEX / EBITDA (%)	29.1%	34.36%	28.31%	21.9%	16.76%	15.76%	14.75%	13.14%
CAPEX / FCF (%)	129.2%	97.23%	46.62%	17.15%	25.05%	22.33%	21.9%	18.97%
Items per share
Cash flow per share ¹	3.862	4.096	2.174	2.046	2.076	2.338	3.284	4.097
Change	-	6.05%	-46.92%	-5.86%	1.44%	12.64%	40.45%	24.75%
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	30.56	34.39	35.35	35.17	37.39	38.72	41.49	45.77
Change	-	12.53%	2.78%	-0.5%	6.32%	3.54%	7.16%	10.32%
EPS ¹	2.24	3.24	0.74	-0.46	0.86	0.756	1.728	2.429
Change	-	44.64%	-77.16%	-162.16%	286.96%	-12.1%	128.53%	40.61%
Nbr of stocks (in thousands)	55,289	55,524	55,832	56,027	56,291	56,436	56,436	56,436
Announcement Date	17/02/22	22/02/23	21/02/24	20/02/25	24/02/26	-	-	-